Isoprivir (Inosine Pranobex)

Inosine Pranobex stimulates lymphocyte proliferation and boosts interferon production, which together enhance the host’s immune defenses and help limit viral replication across a range of infections.

The specific dose of Isoprivir is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. Dosage regimens are not standardized and should follow the prescriber’s instructions.

Safety data for Inosine Pranobex in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified health professional.

To request Isoprivir, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike direct‑acting antivirals that target specific viral enzymes, Isoprivir acts as an immunomodulator, enhancing the host’s immune response. This mechanism can be advantageous in infections where immune support is beneficial, but it may be less specific than agents that inhibit viral replication directly.

Isoprivir should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Isoprivir is taken orally, typically as a tablet, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water and follow the dosing schedule provided by the healthcare professional.

Serious adverse events, though rare, can include severe allergic reactions such as anaphylaxis, significant changes in blood counts like leukopenia, and liver function abnormalities. Patients should seek immediate medical attention if they experience symptoms such as difficulty breathing, rash, or jaundice.

Isoprivir is contraindicated in individuals with known hypersensitivity to Inosine Pranobex or any of its excipients. Caution is advised for patients with severe immunosuppression, uncontrolled autoimmune disease, or those receiving live vaccines.